Trial
NCT04615949
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Cardiol Therapeutics Inc.
Collaborators
—
Condition
COVID-19
Intervention
Cannabidiol, pharmaceutically produced with < 5 ppm THC
Why stopped
The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-21